Sun Pharmaceutical Industries and the Technion – Israel Institute of Technology announced that their respective subsidiaries have entered into an exclusive worldwide research and license agreement that can potentially lead to the development of novel anti-cancer drugs.

The agreement aims at the development of a joint project, based on new findings by Nobel Prize laureate Distinguished Professor Aaron Ciechanover, Dr. Gila Maor and Professor Ofer Binah.

“We are very excited about this new endeavor between Sun Pharma, with the Technion. We are confident that this collaboration will help us move rapidly forward with our research,” said Ciechanover and Binah. “We explored several collaboration alternatives, but Sun Pharma’s market leadership and its long term commitment have made this collaboration a very high priority for us.”

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

“The Technion is delighted to partner with Sun Pharma to advance this project through pre-clinical development process. This collaboration is an excellent example of interactions between academic discovery and pharmaceutical companies demonstrating the valuable contribution academic institutions can make in bringing new products to help patients worldwide. We sincerely believe this agreement represents the beginning of a long and fruitful relationship between the Technion and Sun Pharma,” said Ciechanover and Binah.

Ciechanover’s lab recently announced a breakthrough in the lab in finding cancer-suppressing proteins.

“This collaboration is part of the various initiatives that Sun Pharma is taking to enhance its specialty pipeline. Mutually beneficial partnerships with independent research institutes, especially world renowned institutes, such as the Technion, is our preferred route to bring to the market, innovative products for unmet medical needs,” said Kirti Ganorkar, Senior Vice President, Business Development, Sun Pharma.